• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Frequency Therapeutics Inc (NQ: FREQ )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Nov 3, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Frequency Therapeutics Inc

    < Previous 1 2 3 4 Next >
    FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
    From Frequency Therapeutics, Inc.
    Via Business Wire
    FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ
    From Kahn Swick & Foti, LLC
    Via Business Wire
    FREQ Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Frequency Therapeutics, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Korro Bio and Frequency Therapeutics Announce Merger Agreement
    From Korro Bio, Inc.
    Via Business Wire
    Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Why Did Bullfrog AI Stock Jump More Than 50%?
    Trading volume and share price for BFRG took significant leaps forward on news the digital biopharmaceutical company will partner with Johns Hopkins University. 
    Via MarketBeat
    Topics Artificial Intelligence Initial Public Offering
    Exposures Artificial Intelligence Securities Market
    Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics to Participate at Upcoming March Investor Conferences
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program
    From Frequency Therapeutics
    Via Business Wire
    Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics to Participate in September Investor and Medical Conferences
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program
    From Frequency Therapeutics, Inc.
    Via Business Wire
    Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
    From Frequency Therapeutics, Inc.
    Via Business Wire
    NASDAQ:FREQ Long Term Shareholder Notice: Investigation of Potential Wrongdoing at Frequency Therapeutics, Inc.
    San Diego, CA -- (SBWIRE) -- 09/29/2021 -- Certain directors of Frequency Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties. 
    Via SBWire
    Topics Lawsuit
    Exposures Financial Legal
    Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points
    From Frequency Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.